SCHEDULE: Viking Global Discloses 6.4% Stake in BioMarin

Viking Global Investors LP and its affiliates, along with key executives, have disclosed a collective beneficial ownership of 6.4% in BioMarin Pharmaceutical Inc., totaling 12,288,611 shares.

Summary

• Viking Global Investors LP, along with its affiliated entities and executive committee members O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, collectively beneficially own 12,288,611 shares of BioMarin Pharmaceutical Inc. Common Stock.
• This aggregate ownership represents 6.4% of BioMarin Pharmaceutical Inc.'s outstanding Common Stock, based on 192,001,650 shares outstanding as of June 30, 2025.
• The beneficial ownership is primarily held through various Viking Global entities including Viking Global Equities Master Ltd. (8,044,650 shares), Viking Long Fund Master Ltd. (2,856,671 shares), Viking Global Opportunities Liquid Portfolio Sub-Master LP (1,223,115 shares), and Viking Global Equities II LP (164,175 shares).
• All reported shares are held with shared voting power and shared dispositive power among the reporting persons and their respective managing entities.

Sentiment

Score: 5

Explanation: This is a routine beneficial ownership disclosure (Schedule 13G) indicating a significant but passive stake, providing no direct positive or negative operational or financial news for the issuer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders gain transparency regarding significant institutional ownership in BioMarin Pharmaceutical Inc.

Next Steps

• The reporting persons have agreed to jointly prepare and timely file all future required Forms 3, 4, or 5 or Schedules 13D or 13G, and any amendments thereto, as required by the Securities Exchange Act of 1934.

Key Dates

Keywords

BioMarin Pharmaceutical, BMRN, Viking Global Investors, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing